In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia***Poster 3 Post-assessment*** Survey

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing score of at least 75% on this post-survey, as well as complete the evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

2.What is your area of specialty?

Hematology

Oncology

Other (please specify)

3.How many years have you been in practice?

<1

1-10

11-20

>21

4.Please select the option that best describes your practice setting:

5.Of the patients you will see in the next month, about how many will benefit from the information you learned today?

6.After participating in this activity, how confident are you in the management of patients with ALL in your practice?

7.OA is a 13-year-old male diagnosed with B-cell ALL.

His white blood cell count at diagnosis was 40 x109/L and he did not have CNS involvement.
He received induction on UKALL 2003 and his day 8 bone marrow biopsy showed a rapid early response with 5% blasts.
At the end of induction his bone marrow biopsy showed MRD < 0.01% and he proceeded with reduced-intensity therapy with 1 delayed intensification followed by maintenance therapy for 2.5 years.
At a follow-up appointment 5 years after his diagnosis his parents would like to understand the likelihood of long-term overall survival.

Which of the following is the most appropriate response?(Required.)

Decreased relative to general population

Decreased relative to age-matched population

Similar to general population

Similar to age-matched population

8.After 10 years of follow-up in the UKALL 2003 trial, augmentation of treatment intensity in children and adolescent young adult (AYA) with acute lymphoblastic leukemia (ALL) and minimal residual disease (MRD) > 0.01% at the end of induction was associated with which of the following outcomes?(Required.)

Decrease in event-free survival

Improvement in event-free survival

Improvement in overall survival

No difference in relapse

9.Dosing pegaspargase at 500 U/m2 in patients with elevated risk for hepatoxicity on the GMALL Trial 8/2013 was associated with which of the following outcomes?(Required.)

Acceptable hepatoxicity

No hepatoxicity

Increased efficacy

Decreased efficacy

Evaluation Form
In order to receive a CME/CE certificate for your participation in this activity, please complete this form in its entirety.

10.How committed are you to making changes in your practice based on your participation in this activity?(Required.)

If not committed or do not plan to make changes, please indicate reason

11.Which of the following best describes the impact of this activity on your performance?(Required.)

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

12.Which new strategies/skills/information will you apply to your area of practice?

Recognize the role of treatment of adults, children, and AYAs with ALL based on MRD status

Recall supportive data on pegaspargase dosing strategies in adults with ALL/LBL who also have risk factors for hepatotoxicity

Other (please specify)

13.What barriers do you see to making changes in your practice?

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

17.If you indicated that you perceived commercial bias or influence, please describe:

18.As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

19.Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related ALL:

20.Please let us know who you are so we can connect your responses to your pre-test & application to claim CME credit.

First & Last Name

Degree/Credentials

ZIP/Postal Code

Country

Email Address

21.I certify that I have participated in the continuing education activity entitled, “In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia" and claim 0.5 AMA PRA Category 1 Credit^TM.

Yes

No